Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aildenafil is a synthetic small molecule drug belonging to the class of phosphodiesterase type 5 (PDE5) inhibitors. It is structurally related to sildenafil and vardenafil, and was developed for the treatment of erectile dysfunction. Like other PDE5 inhibitors, aildenafil works by inhibiting the enzyme phosphodiesterase type 5, leading to increased levels of cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This results in relaxation of vascular smooth muscle and increased blood flow, particularly in the corpus cavernosum of the penis during sexual stimulation. Aildenafil has been studied primarily as an oral therapy for erectile dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aildenafil.